Conditions · Pancreatic cancer
Pancreatic cancer — drug options
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALPHASE1NOT_YET_RECRUITING
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
NP137 — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC
SHR-1701 · Apatinib · gemcitabine — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
AGEN2373 · Balstilimab · Cyclophosphamide — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer
Samuraciclib + Gemcitabine & Nab-Paclitaxel — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
JAB-23E73 · JAB-23E73 — 32 sites
- TRIALPHASE3RECRUITING
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate · nab-paclitaxel; gemcitabine — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
EGFR FPBMC — 1 site
- TRIALPHASE2RECRUITING
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Zanidatamab — 28 sites
- TRIALPHASE2RECRUITING
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
Bupivacaine · Hydromorphone · Iopamidol — 1 site
- TRIALPHASE3RECRUITING
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Immuncell-LC · Gemcitabine — 1 site
- TRIALPHASE2RECRUITING
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Riluzole · Placebo — 1 site
- TRIALPHASE1RECRUITING
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
ASP2138 · Pembrolizumab · Oxaliplatin — 46 sites
- TRIALPHASE1 / PHASE2RECRUITING
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VMD-928 100 mg Tablet · VMD-928 Tablet and Pembrolizumab (200 mg) — 15 sites
- TRIALPHASE3RECRUITING
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound
Auricular point stimulation plus dexamethasone · Standard pharmacologic antiemetic regimen — 1 site
- TRIALPHASE1RECRUITING
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
ELI-002 7P · Tislelizumab · mFOLFIRINOX — 7 sites
- EXPANDED ACCESSAVAILABLE
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
DNG64-CAR-V — 1 site
- TRIALPHASE1RECRUITING
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
KST-6051 — 9 sites
- TRIALPHASE2RECRUITING
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
pH-NASOX-Immune Group — 1 site
- TRIALPHASE2RECRUITING
NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Biospecimen Collection · Computed Tomography · Fluorouracil — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
BLEX 404
- TRIALPHASE2RECRUITING
Using Tumor Models to Determine Treatments
Cobimetinib · Ponatinib · Brigatinib — 1 site
- TRIALPHASE2RECRUITING
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Cemiplimab Plus Gemcitabine — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
Biospecimen Collection · Copper Cu 64-DOTA-A2DM · Positron Emission Tomography — 1 site
- TRIALPHASE3RECRUITING
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
XNW28012 for injection · XNW28012 Mimetic for Injection — 48 sites
- TRIALPHASE1NOT_YET_RECRUITING
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
Oncolytic virus Plus Anti-PD1 and Chemotherapy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA — 1 site
- TRIALPHASE2RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Belzutifan — 84 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
CT3001 · FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer
Oncolytic virus VRT106 · Chemotherapy — 1 site
- TRIALPHASE1RECRUITING
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Fulvestrant · 177Lu-DOTATATE — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.